Showing results (11-20 of 37) with videos related to

Sort By:
Pageof 4
American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions|December 14, 2007
Estimating the cost effectiveness of ramipril used for specific clinical indications: comparing the outcomes in four clinical trials with a common economic modelSteven A Grover, Louis Coupal, Ilka Lowensteyn
CMAJ Open|April 7, 2018
Evaluation of the cost-effectiveness of evolocumab in the FOURIER study: a Canadian analysisTodd C Lee, Mohammed Kaouache, Steven A Grover
The American Journal of Cardiology|February 22, 2005
Impact of dyslipidemia associated with Highly Active Antiretroviral Therapy (HAART) on cardiovascular risk and life expectancySteven A Grover, Louis Coupal, Norbert Gilmore, et al.
The Canadian Journal of Cardiology|May 10, 2007
Preventing cardiovascular disease among Canadians: what are the potential benefits of treating hypertension or dyslipidemia?Steven A Grover, Louis Coupal, Mohammed Kaouache, et al.
The Canadian Journal of Cardiology|February 28, 2021
Gambling With Cardiovascular Disease Risk Models: How to Choose and How to UseSteven A Grover, Hiba Jekki, Mohammed Kaouache, et al.
Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation|May 8, 2004
Health-related quality of life in cardiac patients with dyslipidemia and hypertensionLyne Lalonde, Annette O'Connor, Lawrence Joseph, et al.
AIDS (London, England)|December 29, 2004
The cost-effectiveness of highly active antiretroviral therapy, Canada 1991-2001Eduard J Beck, Sundhiya Mandalia, Maurice Gaudreault, et al.
Journal of Occupational and Environmental Medicine|December 5, 2017
The Measurable Benefits of a Workplace Wellness Program in Canada: Results After One YearIlka Lowensteyn, Violette Berberian, Patrick Belisle, et al.
Pageof 4